vs

Side-by-side financial comparison of HACKETT GROUP, INC. (HCKT) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

HACKETT GROUP, INC. is the larger business by last-quarter revenue ($68.8M vs $36.2M, roughly 1.9× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs -11.6%). Over the past eight quarters, InfuSystem Holdings, Inc's revenue compounded faster (6.4% CAGR vs -5.9%).

Hackett Limited is a British multi-channel retailer of clothing for men and boys, with a broad range of apparel and accessories. It was founded in 1983 in London, England. As of June 2019, the company had 160 stores globally, with its flagship store at 14 Savile Row in London. It is owned by both Lebanese holding company M1 Group and American L Capital Asia

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

HCKT vs INFU — Head-to-Head

Bigger by revenue
HCKT
HCKT
1.9× larger
HCKT
$68.8M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+18.7% gap
INFU
7.0%
-11.6%
HCKT
Faster 2-yr revenue CAGR
INFU
INFU
Annualised
INFU
6.4%
-5.9%
HCKT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
HCKT
HCKT
INFU
INFU
Revenue
$68.8M
$36.2M
Net Profit
$4.3M
Gross Margin
70.8%
56.4%
Operating Margin
13.0%
10.3%
Net Margin
6.2%
Revenue YoY
-11.6%
7.0%
Net Profit YoY
36.2%
EPS (diluted)
$0.17
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCKT
HCKT
INFU
INFU
Q1 26
$68.8M
Q4 25
$75.8M
$36.2M
Q3 25
$73.1M
$36.5M
Q2 25
$78.9M
$36.0M
Q1 25
$77.9M
$34.7M
Q4 24
$79.2M
$33.8M
Q3 24
$79.8M
$35.3M
Q2 24
$77.7M
$33.7M
Net Profit
HCKT
HCKT
INFU
INFU
Q1 26
$4.3M
Q4 25
$5.6M
Q3 25
$2.5M
$2.3M
Q2 25
$1.7M
$2.6M
Q1 25
$3.1M
$-267.0K
Q4 24
$3.6M
Q3 24
$8.6M
$1.8M
Q2 24
$8.7M
$717.0K
Gross Margin
HCKT
HCKT
INFU
INFU
Q1 26
70.8%
Q4 25
41.7%
56.4%
Q3 25
40.7%
57.1%
Q2 25
35.4%
55.2%
Q1 25
35.8%
55.2%
Q4 24
39.4%
53.8%
Q3 24
29.2%
53.9%
Q2 24
27.5%
49.5%
Operating Margin
HCKT
HCKT
INFU
INFU
Q1 26
13.0%
Q4 25
12.0%
10.3%
Q3 25
7.5%
10.4%
Q2 25
5.8%
10.5%
Q1 25
5.7%
1.8%
Q4 24
9.8%
7.7%
Q3 24
16.0%
9.2%
Q2 24
16.1%
5.5%
Net Margin
HCKT
HCKT
INFU
INFU
Q1 26
6.2%
Q4 25
7.4%
Q3 25
3.5%
6.2%
Q2 25
2.1%
7.2%
Q1 25
4.0%
-0.8%
Q4 24
4.5%
Q3 24
10.8%
5.1%
Q2 24
11.3%
2.1%
EPS (diluted)
HCKT
HCKT
INFU
INFU
Q1 26
$0.17
Q4 25
$0.20
$0.09
Q3 25
$0.09
$0.11
Q2 25
$0.06
$0.12
Q1 25
$0.11
$-0.01
Q4 24
$0.11
$0.05
Q3 24
$0.31
$0.08
Q2 24
$0.31
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCKT
HCKT
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$3.2M
Total DebtLower is stronger
$78.8M
$19.6M
Stockholders' EquityBook value
$66.0M
$57.3M
Total Assets
$204.4M
$100.6M
Debt / EquityLower = less leverage
1.19×
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCKT
HCKT
INFU
INFU
Q1 26
Q4 25
$18.2M
$3.2M
Q3 25
$13.9M
$955.0K
Q2 25
$10.1M
$720.0K
Q1 25
$9.2M
$1.5M
Q4 24
$16.4M
$527.0K
Q3 24
$10.0M
$380.0K
Q2 24
$19.1M
$146.0K
Total Debt
HCKT
HCKT
INFU
INFU
Q1 26
$78.8M
Q4 25
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Stockholders' Equity
HCKT
HCKT
INFU
INFU
Q1 26
$66.0M
Q4 25
$68.1M
$57.3M
Q3 25
$101.6M
$55.5M
Q2 25
$119.8M
$54.5M
Q1 25
$114.4M
$55.1M
Q4 24
$115.6M
$57.5M
Q3 24
$110.9M
$55.5M
Q2 24
$102.2M
$53.5M
Total Assets
HCKT
HCKT
INFU
INFU
Q1 26
$204.4M
Q4 25
$206.4M
$100.6M
Q3 25
$200.7M
$98.9M
Q2 25
$200.5M
$100.8M
Q1 25
$191.8M
$104.3M
Q4 24
$193.3M
$103.6M
Q3 24
$190.8M
$105.3M
Q2 24
$187.5M
$108.5M
Debt / Equity
HCKT
HCKT
INFU
INFU
Q1 26
1.19×
Q4 25
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCKT
HCKT
INFU
INFU
Operating Cash FlowLast quarter
$7.1M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
19.3%
Capex IntensityCapex / Revenue
3.5%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCKT
HCKT
INFU
INFU
Q1 26
Q4 25
$19.1M
$7.1M
Q3 25
$11.4M
$8.5M
Q2 25
$5.6M
$7.0M
Q1 25
$4.2M
$1.8M
Q4 24
$20.6M
$7.9M
Q3 24
$10.6M
$9.8M
Q2 24
$13.7M
$2.3M
Free Cash Flow
HCKT
HCKT
INFU
INFU
Q1 26
Q4 25
$7.0M
Q3 25
$8.4M
Q2 25
$3.7M
$6.8M
Q1 25
$2.6M
$1.6M
Q4 24
$19.6M
$7.4M
Q3 24
$9.3M
$9.8M
Q2 24
$12.8M
$2.0M
FCF Margin
HCKT
HCKT
INFU
INFU
Q1 26
Q4 25
19.3%
Q3 25
23.1%
Q2 25
4.7%
18.9%
Q1 25
3.4%
4.7%
Q4 24
24.8%
21.9%
Q3 24
11.7%
27.7%
Q2 24
16.5%
5.9%
Capex Intensity
HCKT
HCKT
INFU
INFU
Q1 26
3.5%
Q4 25
0.4%
Q3 25
0.2%
Q2 25
2.4%
0.6%
Q1 25
2.0%
0.4%
Q4 24
1.3%
1.6%
Q3 24
1.5%
0.1%
Q2 24
1.1%
1.0%
Cash Conversion
HCKT
HCKT
INFU
INFU
Q1 26
Q4 25
3.41×
Q3 25
4.47×
3.76×
Q2 25
3.40×
2.70×
Q1 25
1.33×
Q4 24
5.79×
Q3 24
1.23×
5.45×
Q2 24
1.57×
3.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCKT
HCKT

Revenue before reimbursements$36.4M53%
Other$32.0M47%
Reimbursements$405.0K1%

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons